profit from every $100 of sales.
$0$100
Arbutus Biopharma
$3.88+1.57% today
-17.6% in 1 year
1-year low $3.661-year high $5.22
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Arbutus Biopharma sold, what it kept, and what it did with the cash.
Sales went from $39.0 million in 2022 to $14.1 million in 2025, with -$33.5 million of profit last year.
SalesProfit
Arbutus Biopharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Arbutus Biopharma | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Arbutus Biopharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 39 | 18 | 6 | 14 | |
| – | – | – | – | |
| -63 | -78 | -70 | -27 | |
| -62 | -71 | -68 | -33 | |
| -69 | -73 | -70 | -34 | |
| -0.46 | -0.44 | -0.38 | -0.17 | |
| – | – | – | – | |
| -162.0% | -430.2% | -1,133.9% | -192.1% | |
| -178.0% | -401.6% | -1,133.0% | -237.9% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 195 | 144 | 132 | 95 |
| Cash | 31 | 26 | 36 | 18 |
| Total debt | 2 | 2 | 1 | 1 |
| Total liabilities | 59 | 38 | 34 | 18 |
| 137 | 106 | 97 | 77 | |
| 151 | 166 | 186 | 192 | |
| -36.0% | -53.1% | -55.9% | -34.1% | |
| -50.8% | -68.7% | -71.8% | -43.7% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -35 | -86 | -65 | -40 | |
| 1 | 1 | 0 | – | |
| -36 | -87 | -65 | -40 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 9 | 9 | 7 |
Valuation
- –
- –
- –
- 3.1×
- 42.2×
- –
- –
- -6.7%
- -5.6%
- 0.0%
Profitability
- 100.0%
- -192.1%
- -237.9%
- 81.7%
- 56.7%
- -52.6%
- 129.3%
- 58.0%
- 56.9%
- 10.7%
Growth
- −28.8%
- –
- +39.1%
- –
- +15.9%
Financial health
- -0.5×
- 0.00
- 0.2%
- 1,798.5×
- 54.26
- 54.26
- 0.69
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 1%of 958
Bottom 1%of 888
Bottom 3%of 889
Bottom 14%of 987
What analysts expect
- Average price target
- $8.50
- Range
- $8.50 – $8.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | 0.87 | -0.03 | +3,000.0% |
| Mar 23, 2026 | -0.01 | -0.04 | +71.5% |
| Nov 13, 2025 | -0.04 | -0.06 | +28.6% |
| Aug 6, 2025 | 0.01 | -0.02 | +150.0% |
| May 14, 2025 | -0.13 | -0.09 | −44.4% |
| Mar 27, 2025 | -0.07 | -0.08 | +12.5% |
| Nov 6, 2024 | -0.10 | -0.10 | +0.0% |
| Aug 1, 2024 | -0.11 | -0.10 | −10.0% |
News
Arbutus gains on plans to buy back 46M shares in tender offerSeeking Alpha · Sep 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
29No pass
Philip Fisher
47No pass
Peter Lynch
33No pass
Joel Greenblatt
71Pass
Charlie Munger
55No pass
Terry Smith
59No pass
Questions about Arbutus Biopharma
Is Arbutus Biopharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Arbutus Biopharma AI analysis
What does Arbutus Biopharma do?
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. It is in Biotechnology.
Does Arbutus Biopharma pay a dividend?
No. Arbutus Biopharma does not pay a dividend at the moment.
Is Arbutus Biopharma stock halal?
Yes. Arbutus Biopharma passes our halal screen: its business is permitted and its debt is 0.1% of its market value, under the 30% limit. How we check
How has Arbutus Biopharma stock done over the past year?
Down 17.6% over the past twelve months, to $3.88. It traded between $3.66 and $5.22 and is 25.7% below its high.
Who are Arbutus Biopharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Arbutus Biopharma's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.